HSE - PCRS

Application Details

HSE Application ID

HSE100130

HTA Number

26041

HTA Link

https://www.ncpe.ie/depemokimab-exdensur-hta-id-26041/

Drug

depemokimab

Brand

Exdensur®

Applicant

GlaxoSmithKline

Indication Applied For

Indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids (ICS) plus another asthma controller.

Application Date

20/08/2026

Marketing Authorisation Date

12/02/2026

Application Status

Awaiting Proposal from Applicant

29/10/2026

Applicant Meeting Held with CPU

29/10/2026

Rapid Review Completed

22/09/2026

Rapid Review Commissioned

21/08/2026

Pricing and Reimbursement Application Complete

20/08/2026

New Search